In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with ...

5 Integrating testing for other infectious diseases, such as HIV, tuberculosis, and sexually transmitted infections, and non-communicable diseases, such as diabetes and hypertension, is essential.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...